Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer

Breast. 2014 Dec;23(6):816-20. doi: 10.1016/j.breast.2014.08.015. Epub 2014 Sep 26.

Abstract

The purpose of this multicenter prospective and descriptive study was to determine late toxicities and outcomes among patients with non-metastatic breast cancer receiving concurrent bevacizumab (BV) and radiation therapy (RT) in the clinical trials. Early and late toxicities were assessed and evaluation was available for 63 patients (pts) at 12 months. Acute radiation dermatitis was observed in 48 (76%): grade 1 for 27, grade 2 for 17 and grade 3 for 4 pts. Grade 2 acute oesophagitis was observed in one patient (2%). Little toxicity was described 1 year after the completion of RT: 7 pts (12%): grade 1-2 pain, 3 (5%) presented grade 1 fibrosis, and 2 pts (4%) - telangiectasia. One patient (2%) experienced grade 1 dyspnoea. Five grade 1-2 lymphoedema occurred. Only one patient experienced a LEVF value less than 50% one year after the end of RT. In conclusion, the concurrent BV with locoregional RT provides acceptable toxicities.

Keywords: Breast cancer; Concurrent bevacizumab; Radiotherapy.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Angiogenesis Inhibitors / adverse effects*
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Bevacizumab
  • Breast Neoplasms / pathology
  • Breast Neoplasms / therapy*
  • Carcinoma, Ductal, Breast / pathology
  • Carcinoma, Ductal, Breast / therapy*
  • Carcinoma, Lobular / pathology
  • Carcinoma, Lobular / therapy*
  • Chemoradiotherapy, Adjuvant / adverse effects*
  • Dermatitis / etiology
  • Dyspnea / etiology
  • Esophagitis / etiology
  • Female
  • Fibrosis
  • Humans
  • Lymphedema / etiology
  • Middle Aged
  • Neoadjuvant Therapy
  • Prospective Studies
  • Radiation Injuries / etiology*
  • Radiation-Sensitizing Agents / adverse effects
  • Skin / pathology*
  • Telangiectasis / etiology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Radiation-Sensitizing Agents
  • Bevacizumab